Brain Cancer Vaccine Testing Begins
Posted on: Tuesday, 23 October 2007, 12:01 CDT
U.S. medical scientists have started a clinical trial to evaluate a brain cancer vaccine that's used in addition to surgery and chemotherapy.
The New York University Medical Center study will focus on patients with glioblastoma multiforme, a deadly form of brain cancer.
The vaccine, called DCVax-Brain, incorporates proteins found in patients' tumors and is designed to attack cancer cells containing those proteins.
We are really excited about the promise of this vaccine, said Dr. Patrick Kelly, chairman of the center's Department of Neurosurgery. Everything now depends on something in addition to surgery so that these tumors do not recur. A cancer vaccine like this may make a difference in extending life and maintaining a good quality of life.
Kelly and Dr. Michael Gruber will lead the research.
The trial will enroll patients 18 to 65 years old with newly diagnosed glioblastoma multiforme brain cancer who will receive standard primary treatment with surgery followed by radiation with concurrent chemotherapy. Enrolled patients will be randomized to receive the standard of care, and others will receive the standard of care and the vaccine.
The vaccine is manufactured by Northwest Biotherapeutics Inc. of Bothell, Wash.
Source: United Press International
Related Articles
- Oropharyngeal Cancer Patients Experience Post-Surgery Sleep Apnea
- Most prostate cancer patients opt for surgery
- Cancer Patients Celebrate Arrival of Unprecedented Standard of Hospital Care to Delaware Valley
- Help for Cancer Patients Displaced By Hurricane Katrina; Radiation Oncologists Around the Country Open Their Doors to Gulf Coast Patients
- The Leukemia & Lymphoma Society Unveils National Education Program For Elderly Cancer Patients
- FDA Approves an Oral Chemotherapy Pill As Alternative to Standard IV Treatment for Colon Cancer Patients Post-Surgery
- Delay in Radiation Therapy No Risk to Prostate Cancer Patients
- Study of Breast Cancer Patients Showed Regimen Including EMEND-R- -Aprepitant- Prevented Nausea and Vomiting After Chemotherapy in More Patients Than a Standard Regimen
- Surgery Delay for Cancer Patients
- Richland Firm Introduces Promising Isotope for Cancer Treatment; Prostate Cancer Patient Receives New Seed Therapy By IsoRay Medical, Inc. In a Worldwide First for Cesium-131
 |
 |
User Comments (0)
RSS Feeds